GlassScriptPhysician profile
Jose Arocha
NPI 1942200282
$3,676.04
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $1,026 · 2021: $1,041 · 2022: $125 · 2023: $56.24 · 2024: $19.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $898.63 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $728.18 | 2019-2021 | |
| Pfizer INC. | $450.67 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $342.19 | 2019-2020 | |
| Lilly USA, LLC | $254.93 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $166.92 | 2019-2021 | |
| Novo Nordisk INC | $162.74 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $138.68 | 2019-2021 | |
| Amarin Pharma, INC. | $104.53 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.20 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $62.31 | 2019 | |
| Mylan Specialty L.P. | $57.42 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $40.24 | 2020-2021 | |
| Shire North American Group INC | $33.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.58 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.44 | 2019 | |
| Irhythm Technologies, INC. | $19.32 | 2024 | Zio Monitor, Zio Xt Patch |
| Boston Scientific Corporation | $17.93 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.68 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.78 | 2022 | |
| Astellas Pharma US INC | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Arocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.